MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jhsg.2025.100779

Медицинская библиотека · Journal of hand surgery global online · 2025

Value of Early Diagnosis and Treatment of Amyloidosis: A Pilot Study of Synovial Biopsy During Carpal Tunnel Release.

Ruesch Trevor, Khurana Nevil, Hansen Logan, Barkho Katiya, Malewicz Julia, Brennan Benjamin, Day Charles S

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: The purpose of this study is to calculate the value of early diagnosis and treatment of transthyretin amyloidosis with tafamadis prior to the development of the symptoms of heart failure. In this pilot study of 51 patients, we present the validation of a published algorithm for the early identification of patients at risk for amyloidosis via tenosynovial biopsy during carpal tunnel release. In addition, by integrating clinical data from this pilot study with published predictive models, we aim to calculate the value of routine screening biopsies for transthyretin amyloidosis.

METHODS

Patients presenting for carpal tunnel release surgery had a tenosynovial biopsy collected at the time of surgery. Cost information was gathered from hospital records. In conjunction with published models, five incremental cost effectiveness ratio equations were generated to assess the value of these screening biopsies.

RESULTS

Of the 51 biopsied patients, six tested positive for amyloid, and one was started on tafamadis, a disease-modifying medication. Early diagnosis and treatment of patients with New York Heart Association class I (NYHA I) heart failure as opposed to NYHA IV results at a cost of $166,691.49 USD per quality adjusted life year (QALY). When treatment is initiated at NYHA class II stage compared with NYHA class IV, there is a cost of $155,977.22/QALY. For treatment at NYHA class III compared with NYHA class IV, the cost is $75,333.28/QALY.

CONCLUSIONS

This study validates the utility of previous criteria in identifying patients at high risk for systemic amyloidosis earlier in the disease course. Using the commonly accepted willingness to pay threshold of $50,000/QALY, early initiation of tafamadis does not represent a cost effective intervention. Routine biopsy of patients is not cost effective with the current cost of therapy and positivity rates of amyloidosis screening.

TYPE OF STUDY/LEVEL OF EVIDENCE: Prognostic IB.

Для цитирования: Ruesch Trevor, Khurana Nevil, Hansen Logan, Barkho Katiya, Malewicz Julia, Brennan Benjamin, Day Charles S. Value of Early Diagnosis and Treatment of Amyloidosis: A Pilot Study of Synovial Biopsy During Carpal Tunnel Release.. Journal of hand surgery global online. 2025. DOI: 10.1016/j.jhsg.2025.100779.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.